Evidence map›Paper›PMID 27256981›Full record

ArticleOncotarget2016

A Phosphatidic Acid (PA) conveyor system of continuous intracellular transport from cell membrane to nucleus maintains EGF receptor homeostasis.

Karen M Henkels, Taylor E Miller, Ramya Ganesan, Brandon A Wilkins, Kristen Fite, Julian Gomez-Cambronero

Abstract read
In one paragraph

Article in Oncotarget, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed.

  1. Article
  2. Review
  3. Phosphatidic acid signaling and function in nuclei.Progress in lipid research · 2024
    Review
  4. Article
  5. Article
  6. Article
  7. D-series Resolvins activate Phospholipase D in phagocytes during inflammation and resolution.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2020
    Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Karen M HenkelsDepartment of Biochemistry and Molecular Biology, Wright State University Boonshoft School of Medicine, Dayton, OH, USA.
Taylor E MillerDepartment of Biochemistry and Molecular Biology, Wright State University Boonshoft School of Medicine, Dayton, OH, USA.
Ramya GanesanDepartment of Biochemistry and Molecular Biology, Wright State University Boonshoft School of Medicine, Dayton, OH, USA.
Brandon A WilkinsDepartment of Biochemistry and Molecular Biology, Wright State University Boonshoft School of Medicine, Dayton, OH, USA.
Kristen FiteDepartment of Biochemistry and Molecular Biology, Wright State University Boonshoft School of Medicine, Dayton, OH, USA.
Julian Gomez-CambroneroCenter for Experimental Therapeutics and Reperfusion Injury, Brigham and Women Hospital and Harvard Medical School, Boston, MA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The intracellular concentration of the mitogen phosphatidic acid (PA) must be maintained at low levels until the need arises for cell proliferation. How temporal and spatial trafficking of PA affects its target proteins in the different cellular compartments is not fully understood. We report that in cancer cells, PA cycles back and forth from the cellular membrane to the nucleus, affecting the function of epidermal growth factor (EGF), in a process that involves PPARα/LXRα signaling. Upon binding to its ligand, EGF receptor (EGFR)-initiated activation of phospholipase D (PLD) causes a spike in intracellular PA production that forms vesicles transporting EGFR from early endosomes (EEA1 marker) and prolonged internalization in late endosomes and Golgi (RCAS marker). Cells incubated with fluorescent-labeled PA (NBD-PA) show PA in "diffuse" locations throughout the cytoplasm, punctae (small, <0.1 μm) vesicles) and large (>0.5 μm) vesicles that co-localize with EGFR. We also report that PPARα/LXRα form heterodimers that bind to new Responsive Elements (RE) in the EGFR promoter. Nuclear PA enhances EGFR expression, a role compatible with the mitogenic ability of the phospholipid. Newly made EGFR is packaged into PA recycling vesicles (Rab11 marker) and transported back to the cytoplasm and plasma membrane. However, a PLD+PA combination impedes binding of PPARα/LXRα to the EGFR promoter. Thus, if PA levels inside the nucleus reach a certain threshold (>100 nM) PA outcompetes the nuclear receptors and transcription is inhibited. This new signaling function of PLD-PA targeting EGFR trafficking and biphasically modulating its transcription, could explain cell proliferation initiation and its maintenance in cancer cells.

Indexed as

4-Chloro-7-nitrobenzofurazanAnimalsCell Line, TumorCell MembraneCell NucleusChlorocebus aethiopsCOS CellsEndosomesEpidermal Growth FactorErbB ReceptorsHumansLiver X ReceptorsPhosphatidic AcidsPhospholipase DPPAR alphaPromoter Regions, Genetic1-oleoyl-2-((N-(7-(nitro)-2,1,3-benzoxadiazol-4-yl)amino)hexanoyl)glycero-3-phosphate4-Chloro-7-nitrobenzofurazanEpidermal Growth FactorErbB ReceptorsLiver X ReceptorsPhosphatidic AcidsPhospholipase DPPAR alphabreast cancercell signalinggene expressionmammalian cellsphospholipids

Identifiers

PMID27256981
PMCPMC5216919

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.